Halozyme Therapeutics (NASDAQ:HALO – Get Rating) updated its FY 2023 earnings guidance on Tuesday. The company provided EPS guidance of $2.50-$2.65 for the period, compared to the consensus EPS estimate of $2.57. The company issued revenue guidance of $815.00 million-$845.00 million, compared to the consensus revenue estimate of $833.00 million. Halozyme Therapeutics also updated its […]
Halozyme Therapeutics (NASDAQ:HALO – Get Rating) issued an update on its FY 2023 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $2.50-$2.65 for the period, compared to the consensus earnings per share estimate of $2.57. The company issued revenue guidance of $815.00 million-$845.00 million, compared to the consensus revenue estimate […]
Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) have been assigned an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average […]
Should You Buy or Sell Halozyme Therapeutics Stock? Get The Latest HALO Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
Harvest Fund Management Co. Ltd acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) in the fourth quarter, HoldingsChannel reports. The fund acquired 1,002 shares of the biopharmaceutical company’s stock, valued at approximately $57,000. A number of other hedge funds and other institutional investors also recently modified their holdings of the company. […]